Roger C. Lucas Sells 100 Shares of Bio-Techne Corp (TECH) Stock
Bio-Techne Corp (NASDAQ:TECH) Director Roger C. Lucas sold 100 shares of the business’s stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $121.96, for a total value of $12,196.00. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Shares of Bio-Techne Corp (NASDAQ TECH) traded up 0.40% during trading on Thursday, reaching $123.93. The company’s stock had a trading volume of 127,527 shares. The stock has a market cap of $4.63 billion, a P/E ratio of 61.05 and a beta of 0.76. Bio-Techne Corp has a 12-month low of $95.68 and a 12-month high of $124.94. The stock’s 50-day moving average is $121.58 and its 200-day moving average is $114.02.
Bio-Techne Corp (NASDAQ:TECH) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported $1.09 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.10. Bio-Techne Corp had a return on equity of 14.19% and a net margin of 12.93%. The company had revenue of $156.60 million during the quarter, compared to analyst estimates of $150.25 million. During the same quarter last year, the company earned $0.92 earnings per share. The firm’s quarterly revenue was up 16.2% on a year-over-year basis. Equities research analysts anticipate that Bio-Techne Corp will post $3.99 earnings per share for the current fiscal year.
TECH has been the subject of a number of research analyst reports. Deutsche Bank AG boosted their price target on Bio-Techne Corp from $130.00 to $132.00 and gave the stock a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research raised Bio-Techne Corp from a “hold” rating to a “buy” rating and set a $131.00 price target for the company in a report on Thursday, July 6th. BidaskClub raised Bio-Techne Corp from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Finally, Wells Fargo & Company initiated coverage on Bio-Techne Corp in a report on Thursday, July 13th. They set a “market perform” rating for the company. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Bio-Techne Corp presently has an average rating of “Buy” and an average target price of $128.75.
About Bio-Techne Corp
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with MarketBeat.com's FREE daily email newsletter.